The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation and survival. Overexpression and overactivation of members …

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

Histone deacetylases (HDAC) and histone deacetylase inhibitors (HDACi) have greatly
impacted the war on cancer. Their role in epigenetics has significantly altered the …

Simple Summary Thyroid cancer is the most common type of endocrine system malignancy.
The effective diagnosis, precise treatment, and better short and long-term prognosis of …

Accounting for about 2% of cancers diagnosed worldwide, thyroid cancer has caused about
41,000 deaths in 2018. Despite significant progresses made in recent decades in the …

The diagnosis and treatment of recurrence and metastasis in papillary thyroid carcinoma
(PTC) are still clinical challenges. One of the key factors is the lack of specific diagnostic …

Histone deacetylase 6 (HDAC6), by deacetylation of multiple substrates and association
with interacting proteins, regulates many physiological processes that are involved in cancer …

The combination of histone deacetylase inhibitor and BRAF inhibitor (BRAFi) has been
shown to enhance the antineoplastic effect and reduce the progress of BRAFi resistance. In …